Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2024 09:33 ET | Source: Wohl & Fruchter LLP

RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown Laboratories

We are investigating the fairness of the proposed sale of Revance Therapeutics to Crown Laboratories for $6.66 per share in cash.